Focused On-demand Library for Small ribosomal subunit protein RACK1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P63244

UPID:

RACK1_HUMAN

Alternative names:

Cell proliferation-inducing gene 21 protein; Guanine nucleotide-binding protein subunit beta-2-like 1; Guanine nucleotide-binding protein subunit beta-like protein 12.3; Human lung cancer oncogene 7 protein; Receptor for activated C kinase; Receptor of activated protein C kinase 1

Alternative UPACC:

P63244; B3KTJ0; D3DWS0; P25388; P99049; Q53HU2; Q5J8M6; Q5VLR4; Q6FH47

Background:

Small ribosomal subunit protein RACK1, encoded by the gene P63244, serves as a scaffolding protein, crucial for the recruitment and regulation of various signaling molecules. It interacts with a broad spectrum of proteins, influencing cellular processes such as translational repression, ribosome quality control, and protein kinase C stabilization. RACK1's involvement extends to inhibiting SRC kinases, modulating cell cycle progression, and enhancing apoptosis through BAX oligomerization. Additionally, it plays a pivotal role in microbial infections by interacting with pathogens like Y.pseudotuberculosis, enhancing HIV-1 Nef phosphorylation, and facilitating poxvirus mRNA translation.

Therapeutic significance:

Understanding the role of Small ribosomal subunit protein RACK1 could open doors to potential therapeutic strategies.